B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody-Reference-Cited by-同舟云学术

B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody

Published:2010-07-06 Issue:1 Volume:335 Page:213-222
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Herbst Ronald,Wang Yue,Gallagher Sandra,Mittereder Nanette,Kuta Ellen,Damschroder Melissa,Woods Rob,Rowe Daniel C.,Cheng Li,Cook Kim,Evans Krista,Sims Gary P.,Pfarr David S.,Bowen Michael A.,Dall'Acqua William,Shlomchik Mark,Tedder Thomas F.,Kiener Peter,Jallal Bahija,Wu Herren,Coyle Anthony J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference45 articles.

1. Depletion of B Cells in Murine Lupus: Efficacy and Resistance

2. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

3. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab

4. B cells move to centre stage: novel opportunities for autoimmune disease treatment

5. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects;Pharmacological Reports;2024-08-23

2. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?;Clinical and Experimental Immunology;2024-04-20

3. An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes;Frontiers in Immunology;2024-03-07

4. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism;Annals of Clinical and Translational Neurology;2023-10-07

5. Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial;Rheumatology and Therapy;2023-10-04